Wang Xiaoyan, Qiu Miaohan, Qi Jing, Li Jing, Wang Heyang, Li Yi, Han Yaling
1 Graduate school, Dalian Medical University, Dalian 116044, China ; 2 Department of Cardiology, General Hospital of Shenyang Military Region, Shenyang 110016, China.
J Thorac Dis. 2015 Nov;7(11):2041-52. doi: 10.3978/j.issn.2072-1439.2015.11.56.
Data focused on the ischemic events and bleeding events are still limited. We systematically reviewed the current available literature to investigate whether anemia increase incidence of long-term ischemic events and long-term bleeding events in patients undergoing PCI.
PubMed and Embase were searched for case-control studies regarding the impact of anemia on long-term outcomes in patients undergoing percutaneous coronary intervention (PCI). The primary outcome was long-term ischemic events and long-term bleeding events. Mantel-Haenszel method with random effects model or fixed effects model was used to calculate pooled odds ratios (ORs) and 95% confidence intervals (CIs).
Seventeen studies involving 68,528 patients (17,123 anemic patients and 51,405 non-anemic patients) were included. Pooled analysis suggested that anemic patients were at higher risk for long-term composite ischemic events (OR: 1.95, 95% CI, 1.21-3.14, P<0.01, I(2)=84%), long-term reinfarction (0R: 1.63, 95% CI, 1.16-2.28, P<0.01, I(2)=82%) and long-term bleeding events (OR: 2.89, 95% CI, 1.68-4.98, P<0.001, I(2)=89%). Anemia was also associated with long-term mortality (OR: 3.20, 95% CI, 2.72-3.75, P<0.01, I(2)=65%) and major adverse cardiac events (MACE) (OR: 2.06, 95% CI, 1.48-2.86, P<0.01, I(2)=91%).
Anemic patients undergoing PCI are at higher risk for both long-term ischemic events and bleeding events, and also at higher risk for long-term mortality and MACE. There's a need for further clarification and consistency regarding dosage, timing and duration of antithrombotic therapy for the prevention of ischemic events and bleeding events in anemic patients.
关于缺血事件和出血事件的数据仍然有限。我们系统地回顾了当前可用的文献,以调查贫血是否会增加接受经皮冠状动脉介入治疗(PCI)患者的长期缺血事件和长期出血事件的发生率。
在PubMed和Embase数据库中检索关于贫血对接受经皮冠状动脉介入治疗(PCI)患者长期预后影响的病例对照研究。主要结局是长期缺血事件和长期出血事件。采用随机效应模型或固定效应模型的Mantel-Haenszel方法计算合并比值比(OR)和95%置信区间(CI)。
纳入了17项研究,共68528例患者(17123例贫血患者和51405例非贫血患者)。汇总分析表明,贫血患者发生长期复合缺血事件的风险更高(OR:1.95,95%CI,1.21-3.14,P<0.01,I²=84%)、长期再梗死(OR:1.63,95%CI,1.16-2.28,P<0.01,I²=82%)和长期出血事件(OR:2.89,95%CI,1.68-4.98,P<0.001,I²=89%)。贫血还与长期死亡率(OR:3.20,95%CI,2.72-3.75,P<0.01,I²=65%)和主要不良心脏事件(MACE)(OR:2.06,95%CI,1.48-2.86,P<0.01,I²=91%)相关。
接受PCI的贫血患者发生长期缺血事件和出血事件的风险更高,发生长期死亡率和MACE的风险也更高。对于预防贫血患者的缺血事件和出血事件,抗血栓治疗的剂量、时机和持续时间需要进一步明确和统一。